Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Do statins play a role in renoprotection?

Kasahara M, Nakagawa T, Yokoi H, Kuwabara T, Yasuno S, Mori K, Mukoyama M, Ueshima K.

Clin Exp Nephrol. 2014 Apr;18(2):282-5. doi: 10.1007/s10157-013-0928-z. Epub 2014 Jan 10. Review.

PMID:
24408222
2.

Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: rationale and design of the ASsessment of clinical Usefulness in CKD patients with Atorvastatin (ASUCA) trial.

Ueshima K, Kasahara M, Koya D, Babazono T, Sato T, Imamoto M, Yasuno S, Fujimoto A, Tanaka S, Kimura G, Nakao K.

Clin Exp Nephrol. 2013 Apr;17(2):211-7. doi: 10.1007/s10157-012-0676-5. Epub 2012 Sep 6.

PMID:
22948416
3.

[Statins in patients with kidney failure: efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplant].

Karie S, Launay-Vacher V, Deray G, Isnard-Bagnis C.

Presse Med. 2006 Feb;35(2 Pt 1):219-29. Review. French.

PMID:
16493350
4.

Epidemiology of dyslipidemia in chronic kidney disease.

Iseki K.

Clin Exp Nephrol. 2014 Apr;18(2):185-8. doi: 10.1007/s10157-013-0891-8. Epub 2014 Jan 11. Review.

PMID:
24408220
6.

Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis.

Hou W, Lv J, Perkovic V, Yang L, Zhao N, Jardine MJ, Cass A, Zhang H, Wang H.

Eur Heart J. 2013 Jun;34(24):1807-17. doi: 10.1093/eurheartj/eht065. Epub 2013 Mar 6. Review.

7.

[Treatment of dyslipidemia in patients with metabolic syndrome and chronic kidney disease].

Monhart V.

Vnitr Lek. 2009 Jul-Aug;55(7-8):671-8. Review. Czech.

PMID:
19731874
8.

[Statins and kidney disease].

Bigazzi R, Grimaldi D, Bianchi S.

G Ital Nefrol. 2012 Mar-Apr;29(2):160-73. Review. Italian.

PMID:
22538946
9.

3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors prevent the progression of renal dysfunction in Japanese hypertensive patients.

Kuwabara M, Kubo T, Bando K, Hirakawa Y, Kitaoka H, Nishinaga M, Doi YL.

Geriatr Gerontol Int. 2010 Jul;10(3):219-24. doi: 10.1111/j.1447-0594.2010.00584.x. Epub 2010 Feb 4.

PMID:
20141537
10.

Statins and lipid-lowering strategies in cardiorenal patients.

Bianchi S, Grimaldi D, Bigazzi R.

Contrib Nephrol. 2011;171:143-50. doi: 10.1159/000327139. Epub 2011 May 23. Review.

PMID:
21625103
11.

Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).

Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Charlton-Menys V, DeMicco DA, Fuller JH; CARDS Investigators.

Am J Kidney Dis. 2009 Nov;54(5):810-9. doi: 10.1053/j.ajkd.2009.03.022. Epub 2009 Jun 21.

PMID:
19540640
12.

Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction?

Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DP.

Expert Opin Pharmacother. 2015;16(10):1449-61. doi: 10.1517/14656566.2015.1053464. Epub 2015 Jun 3. Review.

PMID:
26037614
13.

Statins in chronic kidney disease: cardiovascular risk and kidney function.

Deedwania PC.

Postgrad Med. 2014 Jan;126(1):29-36. doi: 10.3810/pgm.2014.01.2722. Review.

PMID:
24393749
14.

Dyslipidemia and progression of kidney disease: role of lipid-lowering drugs.

Campese VM.

Clin Exp Nephrol. 2014 Apr;18(2):291-5. doi: 10.1007/s10157-014-0934-9. Epub 2014 Feb 18. Review.

PMID:
24535025
15.

Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study.

Athyros VG, Karagiannis A, Ganotakis ES, Paletas K, Nicolaou V, Bacharoudis G, Tziomalos K, Alexandrides T, Liberopoulos EN, Mikhailidis DP; Assessing The Treatment Effect in Metabolic syndrome without Perceptible diabeTes (ATTEMPT) Collaborative Group.

Curr Med Res Opin. 2011 Aug;27(8):1659-68. doi: 10.1185/03007995.2011.595782. Epub 2011 Jun 30.

PMID:
21714711
16.

Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study.

Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK; TNT (Treating to New Targets) Investigators.

J Am Coll Cardiol. 2008 Apr 15;51(15):1448-54. doi: 10.1016/j.jacc.2007.11.072.

17.

Impact of dietary fiber intake on glycemic control, cardiovascular risk factors and chronic kidney disease in Japanese patients with type 2 diabetes mellitus: the Fukuoka Diabetes Registry.

Fujii H, Iwase M, Ohkuma T, Ogata-Kaizu S, Ide H, Kikuchi Y, Idewaki Y, Joudai T, Hirakawa Y, Uchida K, Sasaki S, Nakamura U, Kitazono T.

Nutr J. 2013 Dec 11;12:159. doi: 10.1186/1475-2891-12-159.

18.

Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis.

Palmer SC, Craig JC, Navaneethan SD, Tonelli M, Pellegrini F, Strippoli GF.

Ann Intern Med. 2012 Aug 21;157(4):263-75. doi: 10.7326/0003-4819-157-4-201208210-00007. Review.

19.

Statin and the risk of renal-related serious adverse events: Analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and other placebo-controlled trials.

Bangalore S, Fayyad R, Hovingh GK, Laskey R, Vogt L, DeMicco DA, Waters DD; Treating to New Targets Steering Committee and Investigators.

Am J Cardiol. 2014 Jun 15;113(12):2018-20. doi: 10.1016/j.amjcard.2014.03.046. Epub 2014 Apr 3. Review.

PMID:
24793673
20.

Statin use in patients with diabetes and kidney disease: the Japanese experience.

Koya D, Campese VM.

J Atheroscler Thromb. 2013;20(5):407-24. Epub 2013 Mar 22. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk